Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12790043 | 0.91 | MEN1 (1.00) | MEN1HSD17B10USP2ALDH1A1TSHR | |
| SCHEMBL12790109 | 0.91 | MEN1 (1.00) | MEN1HSD17B10USP2ALDH1A1TSHR | |
| SCHEMBL12790105 | 0.89 | MEN1 (1.00) | MEN1HSD17B10USP2ALDH1A1TSHR | |
| SCHEMBL18962535 | 0.88 | MEN1 (0.89) | MEN1HSD17B10USP2ALDH1A1TSHR | |
| SCHEMBL12541285 | 0.85 | MEN1 (0.73) | MEN1HSD17B10USP2ALDH1A1TSHR | |
| SCHEMBL18962533 | 0.84 | MEN1 (0.84) | MEN1HSD17B10USP2ALDH1A1TSHR | |
| SCHEMBL18962532 | 0.83 | MEN1 (0.71) | MEN1HSD17B10USP2ALDH1A1TSHR | |
| SCHEMBL14950924 | 0.82 | MEN1 (0.69) | MEN1HSD17B10USP2ALDH1A1KDM4E | |
| SCHEMBL12790050 | 0.81 | MEN1 (1.00) | MEN1HSD17B10USP2ALDH1A1TSHR | |
| SCHEMBL14950833 | 0.78 | MEN1 (0.64) | MEN1HSD17B10USP2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473054-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | UNIV MICHIGAN REGENTS (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160045504-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-02-18 | — | — | US | disclosed |
| US-20160045504-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-02-18 | — | — | US | disclosed |
| US-8993552-B2 | Compositions and methods for treatment of leukemia | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993552-B2 | Compositions and methods for treatment of leukemia | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-03-31 | — | — | US | disclosed |
| US-20110065690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2011029054-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045504-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | MLLT1, MCL1, MLLT3 | MEN1 10/4885HSD17B10 3266/4885USP2 2853/4885 |
| US-20110065690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | MLLT1, MCL1, MLLT3 | MEN1 10/4885HSD17B10 3266/4885USP2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.